Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $35.87, for a total value of $59,113.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) traded up $0.12 during midday trading on Thursday, reaching $37.96. The company’s stock had a trading volume of 441,600 shares, compared to its average volume of 429,476. The stock has a market capitalization of $1,924.68, a price-to-earnings ratio of -16.15 and a beta of -0.82. Aimmune Therapeutics Inc has a 52 week low of $15.97 and a 52 week high of $40.65.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. equities research analysts predict that Aimmune Therapeutics Inc will post -2.51 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Carillon Tower Advisers Inc. purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $58,838,000. Alliancebernstein L.P. increased its position in shares of Aimmune Therapeutics by 109.5% during the fourth quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock worth $52,959,000 after acquiring an additional 731,927 shares during the period. Citadel Advisors LLC increased its position in shares of Aimmune Therapeutics by 3,092.5% during the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock worth $13,873,000 after acquiring an additional 542,111 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $18,702,000. Finally, Vanguard Group Inc. increased its position in shares of Aimmune Therapeutics by 12.6% during the second quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock worth $50,923,000 after acquiring an additional 276,978 shares during the period. 73.14% of the stock is currently owned by institutional investors.
Several equities research analysts have commented on the company. Roth Capital boosted their price objective on Aimmune Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald started coverage on Aimmune Therapeutics in a research note on Tuesday, December 12th. They set an “overweight” rating and a $55.00 price objective for the company. BidaskClub cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Wedbush restated an “outperform” rating on shares of Aimmune Therapeutics in a report on Monday. Finally, Piper Jaffray Companies boosted their target price on Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Aimmune Therapeutics has an average rating of “Buy” and a consensus target price of $57.25.
TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/15/aimmune-therapeutics-inc-aimt-insider-douglas-t-sheehy-sells-1648-shares.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.